In the world of medicine, race-based diagnoses are still very real
We've probably said it a hundred times on Code Switch — biological race is not a real thing. So why is race still used to help diagnose certain conditions, like keloids or cystic fibrosis? On this episode, Dr. Andrea Deyrup breaks it down for us, and unpacks the problems she sees with practicing race-based medicine. (Source: NPR Health and Science)
Source: NPR Health and Science - March 13, 2024 Category: Consumer Health News Authors: Gene Demby Source Type: news
Local CF startup raises largest VC round in Mass. so far this year
A Waltham startup developing new treatments for cystic fibrosis has raised the largest Series C funding round so far in Massachusetts this year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 6, 2024 Category: Pharmaceuticals Authors: Hannah Green Source Type: news
Local CF startup raises one of the largest VC rounds in Mass. so far this year
A Waltham startup developing new treatments for cystic fibrosis has raised the largest Series C funding round so far in Massachusetts this year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 6, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
This Could Be the Next Blockbuster Drug Stock to Buy
Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.#vertex (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Mum Becky Whitfield's proud legacy for her brave cystic fibrosis daughter Elle
EXCLUSIVE: Elle Morris died aged 11 waiting for lifesaving cystic fibrosis drugs on NHS, so on should have been her 18th birthday her mum hosted a charity fundraising ball (Source: Daily Express - Health)
Source: Daily Express - Health - February 11, 2024 Category: Consumer Health News Source Type: news
Vertex plans more launches following 11% jump in product sales
CEO Reshma Kewalramani said Vertex is well on its way to launching five new products by 2028. Up next: New drugs for cystic fibrosis and pain relief. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 6, 2024 Category: Pharmaceuticals Authors: Hannah Green Source Type: news
Vertex's Triple Combo Cystic-fibrosis Drug Meets Main Late-stage Study Goals Vertex's Triple Combo Cystic-fibrosis Drug Meets Main Late-stage Study Goals
Vertex Pharmaceuticals ' experimental cystic-fibrosis treatment met all of its main goals in a late-stage study when tested in patients aged 12 years and older, the company...Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2024 Category: Consumer Health News Tags: Pulmonary Medicine Source Type: news
Ferreting Out the Causes of Cystic Fibrosis
Transgenic ferret models ratted out how a rare cell type affects airway function. (Source: The Scientist)
Source: The Scientist - February 1, 2024 Category: Science Tags: Magazine Issue Source Type: news
How venture philanthropy is changing the game in drug development
The Boston-based JDRF T1D Fund remains one of the more successful examples of the venture philanthropy business model pioneered by groups like the Cystic Fibrosis Foundation in the 1990s and the Michael J. Fox Foundation for Parkinson ’s Research, founded in 2000. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 26, 2024 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Call the Midwife’s Jenny Agutter rails against CF drug ban
Jenny Agutter warns "a generation" of cystic fibrosis patients may die unless they too can access wonder drug Kaftrio on the NHS. (Source: Daily Express - Health)
Source: Daily Express - Health - January 1, 2024 Category: Consumer Health News Source Type: news
